...
首页> 外文期刊>Journal of Surgical Oncology >Liver resection for hepatocellular carcinoma in patients who have undergone prior renal transplantation.
【24h】

Liver resection for hepatocellular carcinoma in patients who have undergone prior renal transplantation.

机译:先前接受肾移植手术的肝细胞癌患者的肝切除术。

获取原文
获取原文并翻译 | 示例

摘要

BACKGROUND AND OBJECTIVES: Because renal transplantation recipients require immunosuppressive drugs, they have a higher incidence of subsequent malignancies. Among them, hepatocellular carcinoma (HCC) is common. Although liver resection remains an option for curing HCC, the role of liver resection in renal transplantation recipients remains unclear. METHODS: A retrospective review of liver resection for newly diagnosed HCC in 680 patients was conducted. Among them, 18 patients had undergone prior renal transplantation (RT group). The patient background, tumor characteristics, early and long-term results after liver resection were compared with the other 662 patients who had not previously undergone renal transplantation (non-RT group). RESULTS: The patient's background characteristics were comparable between RT and non-RT group. The tumor characteristics, postoperative morbidity, and mortality were not significantly different between the two groups. The 5-year disease-free survival rates in RT and non-RT groups were 18.8% and 41.2%, respectively (P = 0.242), whereas 5-year actuarial survival rates in RT and non-RT groups were 59.1% and 58.3%, respectively (P = 0.738). Two patients lost their graft kidney 3 and 8 years after liver resection. CONCLUSION: With careful protection of the graft kidney, liver resection is still a justified treatment option for HCC in patients who have undergone renal transplantation.
机译:背景与目的:由于肾移植受者需要免疫抑制药物,因此其随后发生恶性肿瘤的几率更高。其中,肝细胞癌(HCC)很常见。尽管肝切除仍是治愈HCC的一种选择,但肝切除在肾移植受者中的作用仍不清楚。方法:对680例新近诊断为HCC的肝切除术进行回顾性回顾。其中,有18例患者曾经接受过肾脏移植(RT组)。将患者背景,肿瘤特征,肝切除后的早期和长期结果与其他662例先前未进行肾移植的患者(非RT组)进行了比较。结果:RT和非RT组患者的背景特征相当。两组的肿瘤特征,术后发病率和死亡率无明显差异。 RT和非RT组的5年无病生存率分别为18.8%和41.2%(P = 0.242),而RT和非RT组的5年精算生存率分别为59.1%和58.3% ,分别为(P = 0.738)。肝切除术后3年和8年,两名患者失去了移植肾。结论:在仔细保护移植肾的情况下,肝切除术仍是肾移植患者肝癌的合理治疗选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号